Targeting LIF (both vivo and vitro, including mouse models) reduced cell viability, migration, survivability, tumor growth, and proliferation in breast cancer [116] and triple-negative breast cancer [113], while in type II endometrial cancer [111], tumor growth significantly decreased. The gene discussed is LIF; the disease is endometrial cancer.